Study of IMC-002 in NMOSD patients
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with NMOSD and tested positive for AQP4 antibodies.
- Your disability level is 7.0 or less on the EDSS scale (you can walk with some help).
- You have had at least one NMOSD attack in the last 2 years.
- You haven't taken rituximab or other CD20-targeting drugs in the last 6 months.
- You don't have active infections like HIV, hepatitis C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
Hear when a new Neuromyelitis Optica Spectrum Disorder (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.